Phio Pharmaceuticals Corp. (PHIO) Analysis

PHIO, ALRS and URBN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 28, 2025.

**$PALI – Palisade Bio, Inc.** Palisade Bio Inc.'s main product is the PALI-2108 which is a new oral medication designed to treat swelling, irritation, and soreness in the intestins, while specifically targeting ulcerative colitis and fibrostenotic Crohn’s disease. Currently, $PALI is still in Phase 1b of their clinical trial, meaning they have completed Phase 1a with super positive results, showing strong safety and effectiveness. As of April 9, 2025 they commenced dosing for patients in the P...

Company profile Microbot Medical Inc ($MBOT) is a post clinical stage medical device company featuring their LIBERTY® Endovascular Robotic System. LIBERTY® Endovascular Robotic System Their robotic system has already passed all clinical trials with 100% success rate and reduced radiation by 92% which is groundbreaking in the healthcare industry. Their product already has 9 global patents including 1 in China, where the endovascular demand is surging. Liberty's founding team consists of profes...

If you didn't already know, Phio Pharmaceuticals Inc. is a company that focuses on helping patients with skin cancer. On the 25th (Last Friday), Phio Pharmaceuticals Inc. ($PHIO) surged over 66% in pre market. The news were released at 7:45 AM and said that Phio signed agreement with a U.S manufacturer. This agreement stated that the manufacturer will provide analytical and process development services along with Current Good Manufacturing Practices. This means that by signing the agreement...

In early 2025, Phio Pharmaceuticals Corp rallied by over 500% driven by strong early results from its lead clinical candidate - the PH-762's Phase 1a clinical trial. Their second product, PH-894, is currently in the IND clearance phase, awaiting FDA approval to begin clinical trials. You might be asking: Why hasn't $PHIO submitted the FDA request for their second candidate - the PH-894? This is because they are putting all their ressources in the PH-762 Phase 1b clinical trial which is the most ...

Big moves this morning from $PHIO. The stock shot up over 80% in pre-market, going from around $2.50 to $4.10 in just a few minutes, and it’s not just a random spike. The company dropped two huge updates: Manufacturing agreement signed: They locked in a U.S.-based manufacturer for PH-762, their lead drug candidate. This is a game changer. It means PHIO can now actually produce the drug at scale, which is a key step toward commercialization and *finally* generating revenue. With this in place, t...

$PHIO Short Trade Recap – Textbook VWAP Rejection Date: July 25, 2025 Chart: 5-min Strategy: VWAP Rejection + EMA Cover Indicator Stack: VWAP, EMA (adjusted), custom QuadS tools Entry: I entered short at $3.38 when the first 5-min candle closed below VWAP. The stock had just spiked over 40% and showed signs of exhaustion, with heavy upper wicks and momentum fading fast. VWAP acted as strong resistance and confirmed the weakness I was looking for. Exit / Cover: Covered the trade at $2.8...